Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 1/20 | 0.49 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.49 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.49 |
| ▸ | FYN | P06241 | 5/20 | 0.47 |
| ▸ | AXL | P30530 | 2/20 | 0.47 |
| ▸ | PIM1 | P11309 | 4/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.43 |
| ▸ | KDR | P35968 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 4/20 | 0.43 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.40 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.40 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15747734 | 0.95 | FYN (0.47) | CYP11B1CYP11B2CHEK1FYNAXL | |
| SCHEMBL12858928 | 0.80 | CYP11B1 (0.57) | CYP11B1CYP11B2CHEK1FYNPIM1 | |
| SCHEMBL28363585 | 0.80 | CYP11B1 (0.50) | CYP11B1CYP11B2CHEK1FYNPIM1 | |
| SCHEMBL3386265 | 0.79 | CYP11B1 (0.49) | CYP11B1CYP11B2CHEK1FYNAXL | |
| SCHEMBL16561338 | 0.79 | MKNK1 (0.50) | CYP11B1CYP11B2CHEK1FYNPIM1 | |
| SCHEMBL12594379 | 0.79 | FGFR3 (0.57) | CYP11B1CYP11B2CHEK1FYNPIM1 | |
| SCHEMBL29640802 | 0.79 | CYP11B1 (0.49) | CYP11B1CYP11B2CHEK1FYNAXL | |
| SCHEMBL12897481 | 0.79 | FYN (0.57) | CYP11B1CYP11B2CHEK1FYNPIM1 | |
| SCHEMBL2269551 | 0.78 | CYP11B1 (0.59) | CYP11B1CYP11B2CHEK1FYNPIM1 | |
| SCHEMBL967870 | 0.77 | KCNH2 (0.54) | AXLKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250136568-A1 | FUSED HETEROCYCLIC COMPOUNDS AS PI3KALPHA INHIBITORS | NANJING ZENSHINE PHARMACEUTICALS CO., LTD. (CN) | 2025-05-01 | — | — | US | disclosed |
| CN-119528910-A | Carboxyl condensed ring derivative regulator, preparation method and application thereof | 江苏豪森药业集团有限公司 | 2025-02-28 | — | — | CN | disclosed |
| EP-4444714-A1 | FUSED HETEROCYCLIC COMPOUNDS AS PI3KALPHA INHIBITORS | Nanjing Zenshine Pharmaceuticals Co., Ltd. (CN) | 2024-10-16 | — | — | EP | disclosed |
| CN-118742545-A | Fused heterocyclic compounds as PI3K alpha inhibitors | 南京征祥医药有限公司 | 2024-10-01 | — | — | CN | disclosed |
| WO-2023104111-A1 | FUSED HETEROCYCLIC COMPOUNDS AS PI3KALPHA INHIBITORS | NANJING ZENSHINE PHARMACEUTICALS CO., LTD. (CN) | 2023-06-15 | — | — | WO | disclosed |
| US-10385060-B2 | Piperidine derivative and preparation method and pharmaceutical use thereof | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2019-08-20 | — | — | US | disclosed |
| US-20180298020-A1 | Piperidine Derivative and Preparation Method and Pharmaceutical Use Thereof | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2018-10-18 | — | — | US | disclosed |
| US-10087191-B2 | Piperidine derivative and preparation method and pharmaceutical use thereof | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2018-10-02 | — | — | US | disclosed |
| US-20180170943-A1 | PIPERIDINE DERIVATIVE AND PREPARATION METHOD AND PHARMACEUTICAL USE THEREOF | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2018-06-21 | — | — | US | disclosed |
| US-20180170943-A1 | PIPERIDINE DERIVATIVE AND PREPARATION METHOD AND PHARMACEUTICAL USE THEREOF | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2018-06-21 | — | — | US | disclosed |
| EP-3312184-A1 | PIPERIDINE DERIVATIVE AND PREPARATION METHOD AND PHARMACEUTICAL USE THEREOF | Jiangsu Hengrui Medicine Co., Ltd. (CN) | 2018-04-25 | — | — | EP | disclosed |
| WO-2016202161-A1 | PIPERIDINE DERIVATIVE AND PREPARATION METHOD AND PHARMACEUTICAL USE THEREOF | 江苏恒瑞医药股份有限公司 | 2016-12-22 | — | — | WO | disclosed |
| US-20160304510-A1 | IMIDAZOLONE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | BEIJING FORELANDPHARMA CO. LTD. (CN) | 2016-10-20 | — | — | US | disclosed |
| US-20160304510-A1 | IMIDAZOLONE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | BEIJING FORELANDPHARMA CO. LTD. (CN) | 2016-10-20 | — | — | US | disclosed |
| EP-3072893-A1 | KETONE DERIVATIVES OF IMIDAZOLES, PHARMACEUTICAL COMBINATIONS AND USES THEREOF | Beijing Forelandpharma Co. Ltd. (CN) | 2016-09-28 | — | — | EP | disclosed |
| WO-2015074516-A1 | KETONE DERIVATIVES OF IMIDAZOLES, PHARMACEUTICAL COMBINATIONS AND USES THEREOF | 北京富龙康泰生物技术有限公司 | 2015-05-28 | — | — | WO | disclosed |
| WO-2014079364-A1 | IMIDAZOLONE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | 北京富龙康泰生物技术有限公司 (CN) | 2014-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160304510-A1 | IMIDAZOLONE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | DMPK, MAP3K15, MAP4K2 | CYP11B1 329/4885CYP11B2 294/4885CHEK1 199/4885 |
| US-10385060-B2 | Piperidine derivative and preparation method and pharmaceutical use thereof | GPER1, CYP19A1, PGR | CYP11B1 362/4885CYP11B2 367/4885CHEK1 4394/4885 |
| US-10087191-B2 | Piperidine derivative and preparation method and pharmaceutical use thereof | GPER1, CYP19A1, PGR | CYP11B1 362/4885CYP11B2 367/4885CHEK1 4394/4885 |
| US-20250136568-A1 | FUSED HETEROCYCLIC COMPOUNDS AS PI3KALPHA INHIBITORS | PIK3CA, PIK3CD, PIK3CB | CYP11B1 444/4885CYP11B2 683/4885CHEK1 216/4885 |
| US-20180170943-A1 | PIPERIDINE DERIVATIVE AND PREPARATION METHOD AND PHARMACEUTICAL USE THEREOF | GPER1, CYP19A1, PGR | CYP11B1 362/4885CYP11B2 367/4885CHEK1 4394/4885 |
| US-20180298020-A1 | Piperidine Derivative and Preparation Method and Pharmaceutical Use Thereof | GPER1, CYP19A1, PGR | CYP11B1 362/4885CYP11B2 367/4885CHEK1 4394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.